|

Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Sun Yat-sen University1

Indications

  • Immune-related Adverse Event1
  • Immune Checkpoint Inhibitor1
  • Melanoma1
  • Cancer1

Other1 trial

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.